ICIs associated with MG are programmed cell death-1 (PD-1) blockers (pembrolizumab, nivolumab), followed by blockers of cytotoxic T cell lymphocyte-associated antigen-4 (CTLA-4)—e.g., ipilimumab, and of programmed cell death-ligand 1 (PD-L1) (avelumab, atezlizumab) [12,15,16]. Here, CD274 is linked to myasthenia gravis.